Lund University and Skåne University Hospital reported first-human feasibility and safety results for STEM-PD, a pluripotent stem cell–derived dopamine progenitor product for Parkinson’s disease. In an open-label phase 1/2 trial presented in Nature Medicine, eight patients received intracerebral transplants of the cryopreserved, off-the-shelf therapy, with no serious side effects attributed to the cells during the first year of follow-up. Lead investigator Malin Parmar said the data represent an “important milestone” for regenerative approaches aiming to restore dopamine circuitry, and the paper supports continuing development in larger patient cohorts. Beyond early safety, the trial’s structure—an off-the-shelf, productized progenitor cell—signals a strategic shift for Parkinson’s toward scalable cell manufacturing and standardized delivery, which could influence trial design across the field.